Hecla Mining Company Common Stock vs Dr. Reddy's Laboratories Ltd Common Stock — how do they compare? Hecla Mining Company Common Stock trades at $15.06 (market cap $10.87B), while Dr. Reddy's Laboratories Ltd Common Stock trades at $12.75 (market cap $10.78B). The key difference: Hecla Mining Company Common Stock and Dr. Reddy's Laboratories Ltd Common Stock are close in size by market cap, and Dr. Reddy's Laboratories Ltd Common Stock pays the higher dividend (0.65%). Which is the better fit depends on your goals — on Pluang, investors hold Hecla Mining Company Common Stock for 3 Days and Dr. Reddy's Laboratories Ltd Common Stock for 0 Days on average.
| HL | RDY | |
|---|---|---|
Market Cap | $10.87B | $10.78B |
Volume | 31,516,848 | 2,724,343 |
Sector | Basic Materials | Health |
52-Week High | $31.81 | $15.38 |
52-Week Low | $11.97 | $11.38 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $10.40B | $10.68B |
Dividend Yield | 0.09% | 0.65% |
Signals from Pluang's Aura AI — not financial advice
Hecla Mining (HL) trades at $16.18, down 3.92% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 51.68% gross margin and 19.15% net income margin, but recent quarterly earnings missed expectations. Positive news highlights a debt-free balance sheet and organic growth targeting over 20 million silver ounces, while institutional activity includes new investments from Bank of America and AlphaGrep.
The outlook is mixed: analyst consensus is a Buy with a $23.44 price target, implying 45% upside, but technical indicators signal near-term pressure. Key risks include silver price volatility and execution of growth projects. The stock presents a value opportunity for long-term investors if operational targets are met.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Hecla Mining is a precious metals producer focused on silver and gold. It operates mines in the United States and Canada.
Read more on HL →Dr. Reddy's Laboratories Ltd. develops and manufactures generic medicines, active pharmaceutical ingredients (APIs), biosimilars, and over-the-counter (OTC) products, headquartered in Hyderabad, India, with therapeutic focus areas spanning gastrointestinal, cardiovascular, oncology, and dermatology.
Read more on RDY →